Abbott Laboratories Stock
Abbott Laboratories Stock
Pros and Cons of Abbott Laboratories in the next few years
Pros
Cons
Performance of Abbott Laboratories vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | -1.530% | -2.194% | 2.741% | 9.449% | 3.689% | -4.311% | 36.482% |
| Johnson & Johnson | -1.200% | 0.013% | 3.457% | -1.566% | 5.664% | 6.552% | 26.561% |
| Elanco Animal Health Inc. | -1.330% | -0.850% | -1.597% | 18.297% | -3.402% | -52.733% | - |
| Biogen Inc. | 1.070% | -1.550% | -2.867% | -24.958% | -24.576% | -30.487% | -16.561% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Examining the financials of the pharmaceutical giant Abbott Laboratories, with its ticker symbol ABT, one can't help but form an initial impression tinged with intrigue. Abbott stands as a prominent entity in the healthcare sector, known for its diversified portfolio ranging from medical devices to nutritional products and branded generic medications. This diversity is reflected in its robust financial statements, showcasing the company's significant market presence and operational efficiency.
The sheer magnitude of Abbott's total assets, which hovered consistently above the $70 billion mark from 2020 to 2022, signals a company with considerable resources and a solid financial foundation. Across the same period, the evolution of its balance sheet reveals a healthy balance between liabilities and stockholder equity, pointing to sound financial management. The company's liquidity, as illustrated by its cash reserves, provides confidence in Abbott's ability to meet short-term obligations and invest in growth opportunities.
Profitability and Revenue Streams Abbott has demonstrated an admirable profit margin and a stable operating margin, hinting at its efficiency in converting revenue into profit and managing its operational expenses. The company's net income has shown relative growth, especially when evaluating the year-over-year rise from 2020 to 2022, indicating a consistent upward trajectory in profitability.
Comments
News
Abbott Laboratories' Best Segment Just Got Even Better: Is the Stock a Buy?
Over the past few years, Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device business, but it was later able to smooth out those
3 Ultra-Safe Dividend Stocks for Retirees to Buy and Hold
Dividend growth stocks can make for ideal investment options whether you're a retiree or a long-term investor. The types of businesses that increase their payouts on a regular basis normally have a
2 Stocks That Are Passive Income Machines to Buy and Hold Forever
Among the many corporations that pay a dividend, some do so unpredictably and irregularly. Others rarely raise their payouts -- perhaps once every few years -- while others still quickly resort to